Accro Bioscience and Fosun enrol first patient in Phase 2/3 trial of AC-201 for vitiligo
What's the deal? Accro Bioscience, a clinical-stage company focused on inflammatory and autoimmune diseases, announced on 11 November 2026 that the first patient has been enrolled in a Phase 2/3 trial of AC-201, an oral small-molecule inhibitor of the TYK2/JAK1 enzymes, for non-segmental vitiligo — the most common type of the skin-pigment-loss condition. The trial is run by partner Shanghai Fosun Pharmaceutical (Fosun code FXS5626) and follows China's NMPA clearance of the trial application in September 2026. The Phase 2 stage plans to enrol 120 patients, with efficacy assessed at week 24.
Why it matters: Vitiligo is a chronic autoimmune condition in which the immune system destroys pigment-producing cells, often striking visible areas such as the face and hands and carrying a heavy psychosocial burden; there is no cure. AC-201 targets immune-signalling pathways implicated in the disease and is already in Phase 2 for plaque psoriasis (completed) and non-infectious uveitis (ongoing) in China. An oral, first-in-class option for vitiligo would address significant unmet need, and the licensing partnership with Fosun extends the asset's reach in a large market outside the US and Europe.
Read more: BioSpace, 11 November 2026